The Fort Worth Press - Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

USD -
AED 3.672495
AFN 64.000314
ALL 82.253977
AMD 360.509431
ANG 1.790403
AOA 917.499428
ARS 1552.284702
AUD 1.48346
AWG 1.8025
AZN 1.697632
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377331
BIF 3007.507166
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.778804
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.42811
CDF 2317.999791
CHF 0.838815
CLF 0.025259
CLP 994.110012
CNY 6.66455
CNH 6.665535
COP 3315.05
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.328012
CZK 22.107101
DJF 177.720338
DKK 6.781775
DOP 60.559465
DZD 136.951012
EGP 53.7264
ERN 15
ETB 164.140883
EUR 0.90739
FJD 2.296803
FKP 0.758367
GBP 0.756145
GEL 2.594965
GGP 0.758367
GHS 11.73543
GIP 0.758367
GMD 73.501804
GNF 8860.460038
GTQ 7.643069
GYD 209.144677
HKD 7.846205
HNL 26.886001
HRK 6.831965
HTG 131.024035
HUF 332.705959
IDR 18268.2
ILS 3.254645
IMP 0.758367
INR 93.45945
IQD 1516.079284
IRR 1925253.999815
ISK 124.130485
JEP 0.758367
JMD 158.919789
JOD 0.709003
JPY 159.245985
KES 129.999866
KGS 87.448984
KHR 4080.072793
KMF 447.497229
KPW 900.00035
KRW 1334.25967
KWD 0.31158
KYD 0.833458
KZT 444.016797
LAK 22523.690592
LBP 89554.848894
LKR 332.782835
LRD 168.006442
LSL 16.919297
LTL 2.95274
LVL 0.60489
LYD 6.462884
MAD 9.981438
MDL 18.311519
MGA 4549.44565
MKD 55.861384
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.524838
MUR 47.860197
MVR 15.410202
MWK 1734.212921
MXN 18.413075
MYR 4.093596
MZN 63.910227
NAD 16.918528
NGN 1348.670466
NIO 36.80602
NOK 9.59563
NPR 149.481136
NZD 1.81649
OMR 0.384501
PAB 1.000032
PEN 3.415635
PGK 4.499381
PHP 63.585016
PKR 276.505202
PLN 3.993785
PYG 6230.864068
QAR 3.64562
RON 4.852297
RSD 106.739941
RUB 82.05711
RWF 1480.116648
SAR 3.756442
SBD 8.098361
SCR 13.825232
SDG 601.499925
SEK 10.096805
SGD 1.287735
SHP 0.758581
SLE 23.049694
SLL 20969.503664
SOS 571.501363
SRD 37.437951
STD 20697.981008
STN 22.292284
SVC 8.750364
SYP 13002.000337
SZL 16.918877
THB 33.77702
TJS 9.216015
TMT 3.51
TND 3.026264
TOP 2.40776
TRY 50.414697
TTD 6.771395
TWD 32.925901
TZS 2650.002957
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12019.053598
VES 914.603599
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 595.208663
XAG 0.021073
XAU 0.000259007303
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 595.208663
XPF 108.509428
YER 236.503646
ZAR 16.92348
ZMK 9001.222553
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.06566
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 28 to January 30, 2025 at the Borgata Hotel, Atlantic City, New Jersey.

Text size:

Presentation Details:
Acurx Pharmaceuticals, Inc. Presentation: Wednesday, January 29st at 10 am ET

Interested parties can register to attend here.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis(anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year. The Company's preclinical pipeline includes development of an oral product candidate for treatment of Acute Bacterial Skin and Skin Structure Infections, upon which a development program for treatment of inhaled anthrax is being planned in parallel.

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com

Forward-Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2023, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

Investor Contact: Acurx Pharmaceuticals, Inc.
David P. Luci
President & CEO
Tel: 917-533 1469
Email: [email protected]

SOURCE: Acurx Pharmaceuticals, Inc.

J.M.Ellis--TFWP